| Patients treated with the SQ-grass SLIT-tablet, N (%) |
1,109 (100.0) |
| Median Age, y (range) |
35.0 (11-80) |
| Sex, N (%) |
|
| Men |
520 (46.9) |
| Women |
589 (53.1) |
| Patients with asthma, N (%) |
249 (22.5) |
| Patients with moderate to severe symptoms in previous season*, N (%) |
|
| Nose |
1,047 (94.4) |
| Eyes |
863 (77.8) |
| Bronchi |
241 (21.7) |
| Patients with symptomatic medication in previous season, N (%) |
920 (83.2) |
| Satisfaction with symptomatic treatment in previous season, N (%) |
|
| Very satisfied |
32 (3.5) |
| Satisfied |
298 (32.6) |
| Dissatisfied |
539 (59.0) |
| Very dissatisfied |
44 (4.8) |
| Missing values |
7 (0.6) |
| Patients with concomitant AIT, N (%) |
75 (6.8) |
| Status of immunotherapy, N (%) |
|
| Patients first treated with AIT |
741 (67.0) |
| Patients treated with the SQ grass SLIT-tablet after previous AIT |
308 (27.8) |
| Patients who changed from another AIT |
57 (5.2) |
| Missing values |
3 (0.3) |
N=Number of patients, SLIT=Sublingual immunotherapy, AIT=Allergy
immunotherapy
*moderate: marked symptoms, moderate interference with the patients daily
activities, severe: considerable interference with the patients daily activities,
unacceptable for the patient |
